LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN PLUS CYCLOPHOSPHAMIDE AS ADJUVANT TREATMENT FOR WOMEN WITH OPERABLE BREAST CANCER

被引：0
|
作者：
Jackson, D. [1 ]
Lee, J. M. [2 ]
Adams, J. [1 ]
Gordois, A. [1 ]
机构：
[1] IMS Hlth, St Leonards, NSW, Australia
[2] Sanofi Aventis Australia Pty Ltd, Macquarie Pk, NSW, Australia
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74342-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A274 / A274
页数：1
相关论文
共 50 条
  • [31] COST EFFECTIVENESS OF ADJUVANT CYCLOPHOSPHAMIDE IN THE TREATMENT OF BREAST CANCER IN SPAIN
    Walter, E.
    Brennig, C.
    Schoellbauer, V
    VALUE IN HEALTH, 2011, 14 (07) : A455 - A455
  • [32] Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide plus methotrexate plus fluorouracil in patients with node positive breast cancer (vol 51, pg 111, 1996)
    Messori, A
    Becagli, P
    Trippoli, S
    Tendi, E
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 51 (05) : 427 - 427
  • [33] Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer
    Diéras, V
    Fumoleau, P
    Romieu, G
    Tubiana-Hulin, M
    Namer, M
    Mauriac, L
    Guastalla, JP
    Pujade-Lauraine, E
    Kerbrat, P
    Maillart, P
    Pénault-Llorca, F
    Buyse, M
    Pouillart, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (24) : 4958 - 4965
  • [34] Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Bear, HD
    Anderson, S
    Smith, RE
    Geyer, CE
    Mamounas, EP
    Fisher, B
    Brown, AM
    Robidoux, A
    Margolese, R
    Kahlenberg, MS
    Paik, S
    Soran, A
    Wickerham, DL
    Wolmark, N
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) : 2019 - 2027
  • [35] Doxorubicin (A) followed by docetaxel (T) versus doxorubicin plus docetaxel (AT) in the adjuvant treatment of breast cancer (BC)
    Di Leo, A
    Crown, J
    Nogaret, LM
    Duffy, K
    Bartholomeus, S
    Dolci, S
    Rowan, S
    O'Higgins, N
    Riva, A
    Piccart, MJ
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S41 - S41
  • [36] Persistent Pain, Sensory Disturbances and Functional Impairment After Adjuvant Chemotherapy for Breast Cancer - Cyclophosphamide, Epirubicin and Fluoruracil Compared with Docetaxel plus Epirubicin and Cyclophosphamide
    Andersen, K. Geving
    Jensen, M. B.
    Kehlet, H.
    Gartner, R.
    Eckhoff, L.
    Kroman, N.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S147 - S147
  • [37] Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: Cyclophosphamide, epirubicin and fluorouracil compared with docetaxel plus epirubicin and cyclophosphamide
    Andersen, Kenneth Geving
    Jensen, Maj-Britt
    Kehlet, Henrik
    Gartner, Rune
    Eckhoff, Lise
    Kroman, Niels
    ACTA ONCOLOGICA, 2012, 51 (08) : 1036 - 1044
  • [38] Phase II trial of docetaxel plus doxorubicin and cyclophosphamide in locally advanced breast cancer (LABC).
    Puertolas, T
    Grandez, R
    de Lobera, AR
    Lao, J
    Herrero, A
    Trufero, JM
    Pazo, R
    Orduña, VA
    Cortes, AA
    Torres, AA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 89S - 89S
  • [39] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin and cyclophosphamide regimen (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in early breast cancer at the Mexican Social Security Institute (IMSS) Mexico
    Valle-Solis, Aura A. Erazo
    Olivares, Guillermo
    Lazaro, Miguel
    Maurel, Frederique
    Robles, Jesus
    ANNALS OF ONCOLOGY, 2006, 17 : 107 - 107
  • [40] Doxorubicin plus ifosfamide as salvage treatment for patients with advanced breast cancer refractory to epirubicin plus cyclophosphamide
    Polyzos, A
    Kosmas, C
    Tsavaris, N
    Markopoulos, C
    Kalahanis, N
    Papadopoulos, O
    Arnaouti, T
    Sfikakis, PP
    CLINICAL DRUG INVESTIGATION, 2000, 19 (05) : 349 - 355
12345